Physician profile
Rafaella Wallace
NPI 1821469107
$2,483.33
in general payments reported to CMS, 2019-2025
29 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $764 · 2023: $456 · 2024: $730 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $379.25 | 2021-2024 | Jakafi |
| Myriad Genetic Laboratories, INC. | $261.85 | 2022-2024 | Myrisk |
| Seagen INC. | $242.64 | 2021-2023 | Tukysa |
| Janssen Scientific Affairs, LLC | $157.87 | 2023-2024 | Darzalex, Carvykti, Talvey |
| Glaxosmithkline, LLC. | $152.95 | 2021-2025 | Jemperli |
| Blueprint Medicines Corporation | $147.83 | 2022-2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $137.52 | 2023-2024 | Lynparza |
| Janssen Biotech, INC. | $136.52 | 2024 | Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $135.54 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Sobi, INC | $109.06 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $92.22 | 2022 | |
| Daiichi Sankyo INC. | $67.94 | 2023-2024 | Enhertu |
| Gilead Sciences, INC. | $63.20 | 2022-2024 | |
| Celgene Corporation | $47.67 | 2021-2023 | Reblozyl |
| Ipsen Biopharmaceuticals, INC | $40.87 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $32.19 | 2024 | Xpovio |
| Shield Therapeutics INC | $30.97 | 2024 | |
| Pfizer INC. | $30.87 | 2023-2024 | |
| Amgen INC. | $27.94 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.16 | 2024 | |
| Genzyme Corporation | $24.83 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.79 | 2025 | Libtayo |
| Tempus Ai, INC | $21.24 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.11 | 2022 | |
| Stemline Therapeutics INC. | $17.24 | 2024 | Orserdu |
| Beigene USA, INC. | $16.12 | 2025 | Brukinsa |
| Becton, Dickinson and Company | $14.70 | 2024 | Trek |
| Genentech USA, INC. | $14.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.98 | 2025 | Iclusig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafaella Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.